Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
 Blood, 1 October 2008, Vol. 112, No. 7, pp. 2687-2693.
Prepublished online as a Blood First Edition Paper on July 14, 2008; DOI 10.1182/blood-2008-03-147025.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Appendix
Right arrow All Versions of this Article:
blood-2008-03-147025v1
112/7/2687    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geisler, C. H.
Right arrow Articles by Elonen, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geisler, C. H.
Right arrow Articles by Elonen, E.
Related Collections
Right arrow Free Research Articles
Right arrow Clinical Trials and Observations
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

CLINICAL TRIALS AND OBSERVATIONS

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Christian H. Geisler1, Arne Kolstad2, Anna Laurell3, Niels S. Andersen1, Lone B. Pedersen1, Mats Jerkeman4, Mikael Eriksson4, Marie Nordström5, Eva Kimby5, Anne Marie Boesen6, Outi Kuittinen7, Grete F. Lauritzsen2, Herman Nilsson-Ehle8, Elisabeth Ralfkiær1, Måns Åkerman4, Mats Ehinger4, Christer Sundström3, Ruth Langholm2, Jan Delabie2, Marja-Liisa Karjalainen-Lindsberg9, Peter Brown1, Erkki Elonen9, and for the Nordic Lymphoma Group

1 Rigshospitalet, Copenhagen, Denmark; 2 Norwegian Radium Hospital, Oslo, Norway; 3 Uppsala University Hospital, Uppsala, Sweden; 4 Lund University Hospital, Lund, Sweden; 5 Karolinska Institute, Stockholm, Sweden; 6 Aarhus University Hospital, Aarhus, Denmark; 7 Oulu University Hospital, Oulu, Finland; 8 Sahlgrenska Hospital, Gothenburg, Sweden; and 9 Helsinki University Central Hospital, Helsinki, Finland

Mantle cell lymphoma (MCL) is considered incurable. Intensive immunochemotherapy with stem cell support has not been tested in large, prospective series. In the 2nd Nordic MCL trial, we treated 160 consecutive, untreated patients younger than 66 years in a phase 2 protocol with dose-intensified induction immunochemotherapy with rituximab (R) + cyclophosphamide, vincristine, doxorubicin, prednisone (maxi-CHOP), alternating with R + high-dose cytarabine. Responders received high-dose chemotherapy with BEAM or BEAC (carmustine, etoposide, cytarabine, and melphalan/cyclophosphamide) with R-in vivo purged autologous stem cell support. Overall and complete response was achieved in 96% and 54%, respectively. The 6-year overall, event-free, and progression-free survival were 70%, 56%, and 66%, respectively, with no relapses occurring after 5 years. Multivariate analysis showed Ki-67 to be the sole independent predictor of event-free survival. The nonrelapse mortality was 5%. The majority of stem cell products and patients assessed with polymerase chain reaction (PCR) after transplantation were negative. Compared with our historical control, the Nordic MCL-1 trial, the event-free, overall, and progression-free survival, the duration of molecular remission, and the proportion of PCR-negative stem cell products were significantly increased (P < .001). Intensive immunochemotherapy with in vivo purged stem cell support can lead to long-term progression-free survival of MCL and perhaps cure. Registered at www.isrctn.org as #ISRCTN 87866680.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
C. S. Tam, R. Bassett, C. Ledesma, M. Korbling, A. Alousi, C. Hosing, P. Kebraei, R. Harrell, G. Rondon, S. A. Giralt, et al.
Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma
Blood, April 30, 2009; 113(18): 4144 - 4152.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020